- Home
- RPAY vs MRVI Comparison
RPAY vs MRVI Comparison
Compare RPAY & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPAY
- MRVI
- Stock Information
- Founded
- RPAY 2006
- MRVI 2014
- Country
- RPAY United States
- MRVI United States
- Employees
- RPAY N/A
- MRVI N/A
- Industry
- RPAY Business Services
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- RPAY Consumer Discretionary
- MRVI Health Care
- Exchange
- RPAY Nasdaq
- MRVI Nasdaq
- Market Cap
- RPAY 469.0M
- MRVI 376.2M
- IPO Year
- RPAY N/A
- MRVI 2020
- Fundamental
- Price
- RPAY $5.03
- MRVI $3.46
- Analyst Decision
- RPAY Buy
- MRVI Hold
- Analyst Count
- RPAY 9
- MRVI 9
- Target Price
- RPAY $7.22
- MRVI $4.54
- AVG Volume (30 Days)
- RPAY 979.4K
- MRVI 1.6M
- Earning Date
- RPAY 11-11-2025
- MRVI 11-06-2025
- Dividend Yield
- RPAY N/A
- MRVI N/A
- EPS Growth
- RPAY N/A
- MRVI N/A
- EPS
- RPAY N/A
- MRVI N/A
- Revenue
- RPAY $310,367,000.00
- MRVI $219,830,000.00
- Revenue This Year
- RPAY $0.04
- MRVI N/A
- Revenue Next Year
- RPAY $7.72
- MRVI $7.27
- P/E Ratio
- RPAY N/A
- MRVI N/A
- Revenue Growth
- RPAY 1.45
- MRVI N/A
- 52 Week Low
- RPAY $3.59
- MRVI $1.67
- 52 Week High
- RPAY $9.75
- MRVI $8.29
- Technical
- Relative Strength Index (RSI)
- RPAY 53.31
- MRVI 60.24
- Support Level
- RPAY $4.30
- MRVI $3.37
- Resistance Level
- RPAY $4.75
- MRVI $3.55
- Average True Range (ATR)
- RPAY 0.21
- MRVI 0.18
- MACD
- RPAY 0.04
- MRVI -0.01
- Stochastic Oscillator
- RPAY 86.90
- MRVI 62.75
About RPAY Repay Holdings Corporation
Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.